Abstract
Pancreatic cancer is a lethal disease with increasing incidence. Most patients present with advanced disease, for which palliative systemic chemotherapy is the only therapeutic option. Despite improved median survival rates with FOLFIRINOX or gemcitabine chemotherapy compared to the best supportive care, many individual patients may not benefit from chemotherapy. Biomarkers are needed to predict who will benefit from chemotherapy and to monitor a patient’s response to chemotherapy. This review summarizes current research and future perspectives on circulating biomarkers for systemic chemotherapy response.
Highlights
Pancreatic ductal adenocarcinoma (PDAC) is the twelfth most common cancer worldwide.Its incidence is rising; PDAC will likely be the second leading cause of cancer-related deaths in2030, exceeding the mortality from colorectal and breast cancer [1]
Carbohydrate antigen 19-9 (CA19-9) is a sialylated Lewis blood group antigen associated with different cancers, including PDAC [33]
CA19-9 is widely studied as a diagnostic, prognostic and predictive biomarker in PDAC
Summary
Its incidence is rising; PDAC will likely be the second leading cause of cancer-related deaths in. 2030, exceeding the mortality from colorectal and breast cancer [1]. The mortality rate of PDAC is almost equal to the incidence rate, with a 5-year survival rate of only 7.7% [2]. 80% of patients are diagnosed with advanced disease and are not eligible for tumor resection [3]. For those patients, chemotherapy is currently the standard treatment, while more effective therapies are lacking. Pre-operative chemotherapy is likely to be the future standard [4,5,6,7,8,9,10,11]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
